Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: Comparison to cancer-testis (CT-X) antigens (BMC Cancer (2013) 13 (156) DOI: 10.1186/1471-2407-13-156);Epigenetic regulation of L1CAM in endometrial carcinoma: Comparison to cancer-testis (CT-X) antigens

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Schirmer, Uwe ^a   Fiegl, Heidi ^b   Pfeifer, Marco ^a   Zeimet, Alain G ^b   Müller Holzner, Elisabeth ^b   Bode, Peter K ^c   Tischler, Verena ^c   Altevogt, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BISULFITE; CANCER TESTIS ANTIGEN; CELL ADHESION MOLECULE; DNA METHYLTRANSFERASE 1; L1 CELL ADHESION MOLECULE; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MESSENGER RNA; NY ESO 1 ANTIGEN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CHROMOSOME XQ; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; ENDOMETRIUM CARCINOMA; ENZYME REGULATION; EPIGENETICS; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; L1CAM GENE; PRIMARY TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE SECTION; UPREGULATION;

EID: 84875297269     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-018-4928-y     Document Type: Erratum

References (27)

1. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A. L1-CAM in cancerous tissues. Expert Opin Biol Ther 2008, 8(11):1749-1757. 10.1517/14712598.8.11.1749, 18847309.
2. Schafer MK, Altevogt P. L1CAM malfunction in the nervous system and human carcinomas. Cell Mol Life Sci 2010, 67(14):2425-2437. 10.1007/s00018-010-0339-1, 20237819.
3. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr 2012, 6(4):374-384. 10.4161/cam.20832, 22796939.
4. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003, 362(9387):869-875. 10.1016/S0140-6736(03)14342-5, 13678974.
5. Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett 2003, 189(2):237-247. 10.1016/S0304-3835(02)00513-X, 12490317.
6. Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, Moon HY. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 2007, 14(5):1703-1711. 10.1245/s10434-006-9281-8, 17211730.
7. Bondong B, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NFκB activation. Ann Oncol 2012, 23(7):1795-1802. 10.1093/annonc/mdr568, 22228447.
8. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L, Munch M, Muller-Holzner E, Jerabek-Klestil S. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010, 220(5):551-561. 10.1002/path.2673, 20077528.
9. Kallunki P, Edelman GM, Jones FS. Tissue-specific expression of the L1 cell adhesion molecule is modulated by the neural restrictive silencer element. J Cell Biol 1997, 138(6):1343-1354. 10.1083/jcb.138.6.1343, 2132545, 9298989.
10. Kuwajima A, Iwashita J, Murata J, Abe T. The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res 2007, 27(6B):4163-4169.
11. Kato K, Maesawa C, Itabashi T, Fujisawa K, Otsuka K, Kanno S, Tada H, Tatemichi Y, Kotani K, Oikawa H. DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer. Int J Oncol 2009, 35(3):467-476.
12. Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C, Clark SJ. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell 2013, 23(1):9-22. 10.1016/j.ccr.2012.11.006, 23245995.
13. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008, 98(6):1076-1084. 10.1038/sj.bjc.6604278, 2275492, 18334972.
14. Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, Altevogt P. L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol 2010, 11:64. 10.1186/1471-2199-11-64, 2939505, 20799950.
15. Mechtersheimer S, Gutwein P, Agmon LN, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001, 155(4):661-674. 10.1083/jcb.200101099, 2198870, 11706054.
16. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Kruger A. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008, 27(9):1281-1289. 10.1038/sj.onc.1210747, 17952127.
17. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000, 28(8):E32. 10.1093/nar/28.8.e32, 102836, 10734209.
18. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003, 63(22):7641-7645.
19. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol 2003, 3(3):235-240.
20. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005, 21(21):4067-4068. 10.1093/bioinformatics/bti652, 16141249.
21. Kohl A, Giese KP, Mohajeri MH, Montag D, Moos M, Schachner M. Analysis of promoter activity and 5' genomic structure of the neural cell adhesion molecule L1. J Neurosci Res 1992, 32(2):167-177. 10.1002/jnr.490320206, 1404492.
22. Geismann C, Arlt A, Bauer I, Pfeifer M, Schirmer U, Altevogt P, Muerkoster SS, Schafer H. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. Int J Oncol 2011, 38(1):257-266.
23. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, Ben-Ze'ev A. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005, 168(4):633-642. 10.1083/jcb.200408051, 2171754, 15716380.
24. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006, 4(5):339-349. 10.1158/1541-7786.MCR-05-0229, 16687489.
25. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5(8):615-625. 10.1038/nrc1669, 16034368.
26. Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, Pfreundschuh M. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998, 78(3):387-389. 10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2, 9766577.
27. Otto SP, Walbot V. DNA methylation in eukaryotes: kinetics of demethylation and de novo methylation during the life cycle. Genetics 1990, 124(2):429-437. 1203935, 2307364.